Related Experiment Video

Updated: Aug 29, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

New anticoagulants for venous thromboembolic disease

Patrick Chang1

  • 1Jefferson Medical College, Internal Medicine Department, 833 Chestnut Street, Suite 701, Philadelphia, PA 19107, USA. patrick.chang@mail.jefferson.edu

Idrugs : the Investigational Drugs Journal
|January 20, 2004
PubMed

Insights

Researchers are exploring novel anticoagulants to overcome limitations of current therapies for venous thromboembolism (VTE), a condition causing significant mortality. This review details the coagulation cascade and emerging anticoagulant drug candidates.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Hematology

Background:

  • Venous thromboembolic disease (VTE), encompassing deep vein thrombosis and pulmonary embolism, leads to substantial mortality and morbidity.
  • Approximately 260,000 VTE cases are diagnosed annually in the US.
  • Existing treatments like heparin, low-molecular-weight heparins, and warfarin have disadvantages, driving the search for improved anticoagulants.

Purpose of the Study:

  • To review the pathophysiology and regulation of the coagulation cascade.
  • To provide an overview of emerging anticoagulant drugs for VTE prevention and treatment.

Main Methods:

  • Literature review of the coagulation cascade.
  • Summary of prominent anticoagulant drug classes and specific examples.

Main Results:

  • Detailed review of coagulation cascade mechanisms.
  • Identification of various novel anticoagulant agents including tissue factor pathway inhibitor protein, nematode anticoagulant protein, Factor IX inhibitors, anti-Factor Xa inhibitors (e.g., fondaparinux, idraparinux), selective thrombin inhibitors (e.g., ximelagatran), and enhancers of natural anticoagulants (e.g., activated protein C).

Conclusions:

  • Understanding the coagulation cascade is crucial for developing effective anticoagulants.
  • Several promising anticoagulant drug candidates are under investigation to address limitations of current VTE therapies.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...